KRYS
NASDAQKrystal Biotech Inc.
Price$316.60-10.63 (-3.25%)
01:30 PM07:45 PM
News · 26 weeks37-67%
2026-04-192026-10-11
Mix2290d
- Insider9(41%)
- SEC Filings5(23%)
- Other3(14%)
- Earnings2(9%)
- Analyst2(9%)
- Leadership1(5%)
Latest news
25 items- SECSEC Form 8-K filed by Krystal Biotech Inc.8-K - Krystal Biotech, Inc. (0001711279) (Filer)
- PRKrystal Biotech Announces Positive Clinical Data for New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression in Patients with Gorlin SyndromeOver 80% of assessed basal cell carcinoma lesions regressed across three Gorlin syndrome patients treated with KB113 Substantial regression was observed in lesions not directly injected with KB113, consistent with abscopal effect KB113 injections were well tolerated by Gorlin syndrome patients; all reported adverse events were mild to moderate in severity and transient in nature Data will be presented by study investigator Dr. Shireen Guide at the 14th PeDRA Annual Conference, October 15-17, 2026 PITTSBURGH, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) announced today a positive clinical update supporting initial proof of concept for KB113, an
- ANALYSTGoldman resumed coverage on Krystal Biotech with a new price targetGoldman resumed coverage of Krystal Biotech with a rating of Buy and set a new price target of $441.00
- INSIDERSEC Form 4 filed by Director Rossi Dino A4 - Krystal Biotech, Inc. (0001711279) (Issuer)
- INSIDERSEC Form 4 filed by Director Sutherland Everett Rand4 - Krystal Biotech, Inc. (0001711279) (Issuer)
- INSIDERSEC Form 4 filed by Director Mazzacco Catherine4 - Krystal Biotech, Inc. (0001711279) (Issuer)
- INSIDERSEC Form 4 filed by Director Mason Christopher4 - Krystal Biotech, Inc. (0001711279) (Issuer)
- INSIDERSEC Form 4 filed by Director Janney Daniel4 - Krystal Biotech, Inc. (0001711279) (Issuer)
- INSIDERSEC Form 4 filed by Director Gangolli Julian S4 - Krystal Biotech, Inc. (0001711279) (Issuer)
- INSIDERPresident, R&D Krishnan Suma sold $8,982,986 worth of shares (25,000 units at $359.32) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 1,302,145 units (SEC Form 4)4 - Krystal Biotech, Inc. (0001711279) (Issuer)
- INSIDERPresident and CEO Krishnan Krish S sold $8,983,084 worth of shares (25,000 units at $359.32) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 1,347,543 units (SEC Form 4)4 - Krystal Biotech, Inc. (0001711279) (Issuer)
- PRKrystal Biotech to Present at 2026 Cantor Global Healthcare ConferencePITTSBURGH, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) today announced that the Company will participate in the 2026 Cantor Global Healthcare Conference on September 10, 2026, in New York. Management will take part in a fireside chat scheduled at 3:55 pm ET and host investor meetings throughout the day. A webcast of the presentation will be available here beginning at 3:55 pm ET on Thursday, September 10, 2026 and will be posted on the Investors section of the Company’s website. About Krystal Biotech, Inc.Krystal Biotech, Inc. (NASDAQ:KRYS) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, developme
- INSIDERDirector Rossi Dino A gifted 3,691 shares and sold $8,227,953 worth of shares (25,000 units at $329.12), decreasing direct ownership by 36% to 50,000 units (SEC Form 4)4 - Krystal Biotech, Inc. (0001711279) (Issuer)
- SECSEC Form 144 filed by Krystal Biotech Inc.144 - Krystal Biotech, Inc. (0001711279) (Subject)
- ANALYSTRBC Capital Mkts initiated coverage on Krystal Biotech with a new price targetRBC Capital Mkts initiated coverage of Krystal Biotech with a rating of Outperform and set a new price target of $400.00
- PRCosmetic Surgery's Next Debate: Rebuild Tissue, Not Fill ItRENO, Nev., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary - For thirty years the answer to lost facial and body volume has been to put something back in. Fillers occupy space, implants occupy space, and the industry built around them optimized for predictability and reversibility rather than for biology. That framework is now under real pressure, partly because GLP-1's success in weight loss has expanded the population needing volume restoration at a scale the injectable toolkit was never designed for, and partly because the science moved. When dermatologists, facial plastic surgeons and aesthetic medicine specialists gather this week at the Controversies & Conversation
- SECKrystal Biotech Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Krystal Biotech, Inc. (0001711279) (Filer)
- SECSEC Form 10-Q filed by Krystal Biotech Inc.10-Q - Krystal Biotech, Inc. (0001711279) (Filer)
- PRKrystal Biotech Announces Second Quarter 2026 Financial and Operating Results$119.2 million in 2Q VYJUVEK global revenue and $965.9 million since launch Multiple clinical data readouts in 2H 2026 On track for VYJUVEK launches in Spain and Italy later this year Strong balance sheet, ending the quarter with $1.1 billion in cash and investments PITTSBURGH, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company" or "Krystal") (NASDAQ:KRYS) today reported financial results for the second quarter ended June 30, 2026 and provided a business update. "Our second quarter reflects the strength of the Krystal model: a global commercial product that continues to perform, a strong balance sheet, and a pipeline now moving toward multiple registrational readout
- PRKrystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026PITTSBURGH, July 23, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) announced today that it will report its second quarter 2026 financial results on Monday, August 3, 2026, prior to the open of U.S. markets. The Company’s management will also host a conference call and webcast at 8:30 am ET on Monday, August 3, 2026, to discuss the financial results and provide a business update. Investors and the general public can access the live webcast at: https://www.webcaster5.com/Webcast/Page/3018/54300. For those unable to listen to the live webcast, a replay will be available for at least 30 days on the Investors section of the Company’s website at www.krystalbio.c
- SECKrystal Biotech Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Krystal Biotech, Inc. (0001711279) (Filer)
- PRKrystal Biotech Set to Join S&P MidCap 400; Tutor Perini and V2X to Join S&P SmallCap 600NEW YORK, July 20, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400, S&P SmallCap 600: S&P SmallCap 600 constituent Krystal Biotech Inc. (NASD: KRYS) will replace Taylor Morrison Home Corp. (NYSE:TMHC) in the S&P MidCap 400, and Tutor Perini Corp. (NYSE:TPC) will replace Krystal Biotech in the S&P SmallCap 600 effective prior to the opening of trading on Friday, July 24. S&P 500 & 100 constituent Berkshire Hathaway Inc. (NYSE:BRK) is acquiring Taylor Morrison Home in a deal expected to close on or about that date, pending final closing conditions. V2X Inc. (NYSE: VVX) will replace Avanos Medical Inc. (NYSE:AVNS) in the S&P SmallCap 600 effect
- INSIDEREVP, General Counsel Thomas John Charles exercised 1,000 shares at a strike of $179.25 and sold $347,270 worth of shares (1,000 units at $347.27) as part of a pre-agreed trading plan (SEC Form 4)4 - Krystal Biotech, Inc. (0001711279) (Issuer)
- INSIDERPresident, R&D Krishnan Suma sold $7,702,825 worth of shares (25,000 units at $308.11) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 1,378,155 units (SEC Form 4)4 - Krystal Biotech, Inc. (0001711279) (Issuer)
- INSIDERPresident and CEO Krishnan Krish S sold $7,702,984 worth of shares (25,000 units at $308.12) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 1,450,253 units (SEC Form 4)4 - Krystal Biotech, Inc. (0001711279) (Issuer)
KRYS FAQ
7 questionsWhat does Krystal Biotech Inc. do?
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and acne scars; KB407 that is in preclinical stage for cystic...Where does KRYS stock trade?
Krystal Biotech Inc. (KRYS) is listed on NASDAQ.What sector and industry is KRYS in?
Krystal Biotech Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Krystal Biotech Inc. go public?
Krystal Biotech Inc. (KRYS) completed its IPO in 2017.What are analysts saying about KRYS?
Krystal Biotech Inc. has had 8 recent analyst actions on file. The most recent action was from Goldman: Buy on 2026-09-24.What companies are similar to KRYS?
Notable peers in the same industry include LEGN (Legend Biotech Corporation), PRTG (Portage Biotech Inc.), EDSA (Edesa Biotech Inc.), BBI (Brickell Biotech Inc.), MBRX (Moleculin Biotech Inc.). Compare KRYS side-by-side with any of them on Quantisnow.How can I track KRYS on Quantisnow?
Quantisnow aggregates Krystal Biotech Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow KRYS to receive live email and push alerts on every new disclosure.